Cigna (CI) Stock Forecast & Price Target

Cigna Group is positioned to compound earnings through a mix of durable managed care economics and a fast-growing specialty pharmacy platform, with management reaffirming a 10.0%-14.0% long-term adjusted EPS CAGR and at least $45.00 of adjusted EPS by CY30. The thesis is underpinned by Cigna Healthcare’s 6.0%-9.0% earnings growth outlook, a $3.0 billion modernization and productivity initiative, and visible expansion in Select, International, and Stop Loss, while the exit from lower-margin ACA Marketplace business should improve the quality of the book. Evernorth adds further upside through Specialty and Care Services, where revenue growth is supported by a ~$300 billion specialty pharmacy TAM, >1 million complex-condition patients, and a largely transparent Signature PBS transition that management says can preserve margins while broadening adoption.

Cigna Group is viewed negatively because management’s 10.0-14.0% adjusted EPS CAGR through CY30 and at least $45.00 CY30 EPS floor appear demanding rather than reassuring, especially when the company’s own bridge assumes every business performs at the low end of its targets. The outlook also weakens as Cigna Healthcare growth was cut to 6.0-9.0%, Pharmacy Benefit Services was lowered to 0.0-4.0%, and 5-year consolidated cash flow guidance fell to about $50.0B from about $60.0B, signaling less operating momentum. With a near-term shift in PBM contracting and a lack of confidence in execution above the low end, the setup implies elevated risk to earnings delivery despite reaffirmed CY26 adjusted EPS of at least $30.45.